Compare Gilead Sciences, Inc. (GILD) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Western Alliance Bancorporation — how do they compare? Gilead Sciences, Inc. trades at $133.1 (market cap $163.51B), while Western Alliance Bancorporation trades at $84.15 (market cap $8.93B). The key difference: Gilead Sciences, Inc. is far larger — about 18.3× Western Alliance Bancorporation's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | WAL | |
|---|---|---|
Market Cap | $163.51B | $8.93B |
Sector | Health | Financials |
52-Week High | $155.80 | $96.08 |
52-Week Low | $108.22 | $66.70 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Western Alliance Bancorporation (WAL) trades at $83.33, up 3.7% on the day, with a bullish technical signal from moving averages and strong analyst consensus. The stock shows solid fundamentals with a P/E of 9.52, net income margin of 25.63%, and a history of beating earnings estimates in recent quarters. Recent news highlights operational recognition, including being named Arizona's #1 Best Bank by Forbes in June 2026 and announcing a $0.42 dividend for H1-2026.
The outlook is positive given strong profitability, consistent earnings beats, and overwhelming analyst support (79% Buy ratings). Key risks include significant negative operating cash flow in 2025 (-$2.68B) and reliance on financing activities for liquidity. The stock trades below the consensus price target of $90.67, offering potential upside if the company can improve cash generation from operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
